Nitrate

PubMed ID: 27657471

Oral nicorandil roughly halved ischemic episodes in stable angina, consistent with improved coronary perfusion.

PubMed ID: 2129317

Long-acting nitrates reduced pulmonary pressures and ischemia, consistent with improved central and coronary blood flow.

PubMed ID: 2144705

Nicorandil increased exercise time comparably to atenolol and acts via nitrate-like vasodilation—supports blood-flow improvement.

PubMed ID: 1934379

ISDN decreased left-ventricular filling pressure acutely—hemodynamic evidence of blood-flow redistribution and venodilation.

PubMed ID: 1754868

IS-5-MN improved exercise time and reduced anginal episodes—reflects improved myocardial blood flow during stress.

PubMed ID: 1442478

Smaller infarct size suggests preserved myocardial perfusion/oxygen delivery in acute MI subgroup.

PubMed ID: 8627976

Intracoronary nicorandil produced dose-dependent coronary dilation comparable to ISDN — clear vasodilatory/blood-flow effect.

PubMed ID: 7788038

Quantified reduction in exercise-induced myocardial perfusion defect is strong direct evidence of improved regional blood flow.

PubMed ID: 8659199

ISDN reduced femoral vascular resistance in PAD patients (hemodynamic support for increased flow).

PubMed ID: 9068264

ISDN decreased femoral artery resistance index in PAD — clinical evidence for improved limb blood flow.

PubMed ID: 9875113

Sublingual ISDN and intracoronary GTN produced substantial, quantified coronary artery diameter increases — direct evidence of improved conduit blood flow.

PubMed ID: 9596418

High-dose IV ISDN relieved ischemia faster and achieved BP targets more often than sublingual spray — supports acute flow/ischemia relief.

PubMed ID: 9570429

Sublingual nitrates produced faster angina relief (time to pain relief), reflecting rapid coronary vasodilation and improved flow in ischemia.

PubMed ID: 9482291

IV ISDN decreased need for ventilation and improved outcomes in pulmonary edema, indicating improved pulmonary/cardiac oxygen delivery.

PubMed ID: 10987607

High-dose IV ISDN markedly improved oxygen saturation at 1 hour and reduced mechanical ventilation and MI in severe pulmonary edema — direct oxygenation benefit.

PubMed ID: 15791442

Nicorandil infusion improved cardiac sympathetic imaging and remodeling vs ISDN — consistent with better myocardial perfusion and function.

PubMed ID: 14729792

Nicorandil improved coronary flow velocity, ST recovery and wall motion after AMI compared with ISDN — direct microcirculatory benefit.

PubMed ID: 15965356

Long‑term nicorandil improved brachial FMD and prevented carotid IMT progression — objective evidence of improved endothelial function and flow.

PubMed ID: 17641250

GTN and PETN protected against IR‑induced endothelial dysfunction measured by FMD in healthy volunteers — direct evidence of preserved vasodilator function.

PubMed ID: 18726957

Adding local nitrate to lidocaine reduced radial artery spasm and shortened puncture time — practical evidence of improved/local arterial dilation.

PubMed ID: 19957087

PETN improved nitroglycerin-mediated dilation (endothelium-independent) and increased microcirculatory flow velocity in CAD patients.

PubMed ID: 19137320

Topical nitrates healed anal fissures and lowered sphincter pressure, consistent with improved local blood flow and tissue perfusion.

PubMed ID: 20845295

Sublingual ISDN acutely increased urinary flow and reduced residual volume alongside BP reduction—evidence of improved organ perfusion/flow.

PubMed ID: 21240870

Sustained-release ISMN lowered blood pressure and reduced LV mass in dialysis patients — systemic vascular/hemodynamic benefits implying improved flow.

PubMed ID: 20812862

PETN increased circulating endothelial progenitor cells and improved EPC function, implying vascular repair and improved microvascular flow potential.

PubMed ID: 22505376

Higher-dose topical ISDN produced substantially higher short-term healing rates — likely via vasodilatory and perfusion effects.

PubMed ID: 22298019

PETN preserved endothelial function after ischemia better than GTN — supports vascular function preservation.

PubMed ID: 24054756

Topical ISMN reduced pain and straining in fissure patients — consistent with sphincter relaxation and improved local perfusion.

PubMed ID: 23296279

Oral nitrate therapy reduced LV mass, lowered BP and ADMA in dialysis patients—consistent with improved vascular function and flow.

PubMed ID: 23806384

Oral/inorganic nitrate raised plasma nitrite and produced vascular/platelet effects implying improved microvascular function.

PubMed ID: 23338814

Sublingual nitrates measurably increased time to ischemia and coronary blood‑flow responses in obstructive CAD—direct flow effects.

PubMed ID: 30054906

Peri‑procedural isosorbide dinitrate reduced contrast‑induced nephropathy and adverse events—consistent with improved renal perfusion/flow protection.

PubMed ID: 40123490

Isosorbide mononitrate reduced radial artery graft failure, consistent with vascular/protective effects on conduit patency.

PubMed ID: 32731478

Beetroot + phenolic beverages increased frontal cortex oxygenation (StO2 and tHb), providing direct evidence of enhanced cerebral perfusion.

PubMed ID: 9799202

ADMA associated with impaired vasodilation and urinary nitrate; L‑arginine restored vasodilation—mechanistic evidence linking NO pathway to blood flow.

PubMed ID: 9809945

Increased NO biomarkers and major functional improvement in claudication (walking distance) indicate improved limb perfusion.

PubMed ID: 10402369

Raised follicular NOx and improved Doppler flow in poor-responder IVF patients — local blood flow improvement.

PubMed ID: 12189442

IV L-arginine increased NO markers and antioxidant measures and acutely altered vascular-related markers.

PubMed ID: 12419572

Acute oral L-arginine improved flow‑mediated dilation (endothelium-dependent), indicating better conduit blood flow.

PubMed ID: 20354500

Reduced myocardial lactate release after arginine-supplemented cardioplegia suggests improved myocardial oxygen delivery/usage during ischemia/reperfusion.

PubMed ID: 10080465

IV nicorandil with angioplasty improved myocardial recovery and reduced no-reflow, consistent with better flow.

PubMed ID: 10958273

Peri-PCI nicorandil improved metabolic recovery and left-ventricular function implying better myocardial perfusion.

PubMed ID: 11573520

Prophylactic nicorandil markedly lowered intraoperative ischemia — consistent with improved coronary perfusion.

PubMed ID: 11804989

Nicorandil restored ischemic preconditioning and reduced ischemic burden in elderly during PCI — flow-related.

PubMed ID: 12499617

Intracoronary nicorandil markedly reduced no-reflow/slow-flow during atherectomy — strong blood-flow effect.

PubMed ID: 12030342

Nicorandil reduced QT dispersion and arrhythmia during PTCA; suggests protective perfusion/electrical stability effects.

PubMed ID: 12871686

IV nicorandil reduced ischemic ST elevation during balloon occlusion, indicating an effect on ischemic myocardial perfusion.

PubMed ID: 15459610

IV nicorandil blunted ROS surge and reduced no-reflow after PCI, consistent with improved microvascular perfusion.

PubMed ID: 16116055

Large RCT: IV nicorandil improved epicardial/microvascular reperfusion (TIMI flow, ST resolution) with major clinical benefits—strong blood-flow evidence.

PubMed ID: 15901241

Nicorandil prevented local platelet/neutrophil activation during angioplasty, supporting preserved microvascular flow.

PubMed ID: 22484579

Perioperative nicorandil reduced serum brain-injury markers (NSE, S100β) and preserved MMSE scores, consistent with cerebral protection/perfusion benefit.

PubMed ID: 25174952

Peri-PCI nicorandil reduced troponin release and improved LVEF at 6 months, consistent with myocardial perfusion/microvascular benefit.

PubMed ID: 24457276

Intravenous nicorandil reduced index of microcirculatory resistance immediately post-PCI, showing improved microvascular flow.

PubMed ID: 32729923

60-day high-nitrate markedly lowered ambulatory systolic BP and raised plasma nitrate — strong evidence of improved vascular function/flow.

PubMed ID: 32386891

One-week nitrate increases plasma NOx and reduced post-lunch BP — supports improved perfusion.

PubMed ID: 1282609

Reduced post‑ischaemic stunning after angioplasty implies better oxygen delivery/reperfusion protection.

PubMed ID: 8181883

Marked increases in time to ischemia and exercise tolerance reflect improved myocardial perfusion with intermittent nitrates.

PubMed ID: 30701736

Nicorandil (NO donor) reduced peri‑procedural myocardial injury — pharmacologic NO donor evidence of improved myocardial perfusion.

PubMed ID: 16608381

IV propionyl-L-carnitine in dialysis patients improved a blood flow index (ABI) and NO-related markers.

PubMed ID: 16446007

ABI increased and walking distance rose markedly in PAD patients — improved limb perfusion.

PubMed ID: 35010917

Increased estimated VO2max after chronic nitrate+citrulline suggests improved whole‑body oxygen capacity.

PubMed ID: 32326664

Ubiquinol increased NOx by ~+9.3 μM and improved FMD — clear endothelial/blood-flow signal.

PubMed ID: 18250365

Beetroot robustly increased plasma NOx and produced clinically meaningful BP reduction and platelet inhibition (improved perfusion surrogate).

PubMed ID: 27488183

Dietary root juice increased plasma nitrite and reduced platelet aggregation, which can improve microvascular flow.

PubMed ID: 10618560

IV nitroglycerin post‑stenting reduced minor myocardial necrosis, reflecting improved myocardial perfusion.

PubMed ID: 16337497

IV nicorandil around stenting lowered rates of small cardiac marker rises, consistent with better microvascular protection.

PubMed ID: 17134628

Intracoronary nicorandil reduced slow‑flow/no‑reflow incidence vs verapamil—direct improvement in coronary flow.

PubMed ID: 17346816

Peri‑procedural nicorandil reduced cardiac enzyme rises and improved regional wall motion, indicating better reperfusion.

PubMed ID: 28617765

Oral nicorandil before PCI reduced no‑reflow and improved reperfusion indices—direct improvement in coronary microvascular flow.

PubMed ID: 29659585

IV nicorandil (nitrate donor) before/during PCI significantly reduced periprocedural myocardial injury, indicating improved coronary/microvascular perfusion.

PubMed ID: 30174413

Peri‑procedural oral nicorandil lowered troponin/CK‑MB after PCI—consistent with improved myocardial perfusion/reperfusion.

PubMed ID: 29726480

Intracoronary nicorandil reduced no‑reflow and improved TIMI/TMPG and cTFC, showing improved coronary perfusion.

PubMed ID: 37875637

Acute beetroot improved memory and frontal‑lobe tasks consistent with increased cerebral perfusion from nitrate.

PubMed ID: 38783440

Nicorandil given before primary PCI improved ST‑segment resolution (marker of reperfusion) and lowered early troponin rise—strong evidence of improved reperfusion/blood flow.

PubMed ID: 7921519

Oral nicorandil lowered BP dose‑dependently without impairing renal blood flow, showing favorable hemodynamics.

PubMed ID: 8981915

GH increased urinary nitrate/cGMP and raised cardiac output with lower peripheral resistance—shows NO pathway can improve systemic blood flow.

PubMed ID: 8806342

Sublingual nitrates caused significant falls in aortic systolic BP and are directly vasodilatory—strong evidence for improved central arterial/vascular flow.

PubMed ID: 9557281

Vitamin E prevented nitrate tolerance to nitroglycerin and preserved forearm blood-flow responses and platelet cGMP.

PubMed ID: 12727580

Genistein RCT produced a quantified rise in nitrite/nitrate (+21 µmol/L) and improved flow-mediated vasodilation — direct evidence of improved endothelial function.

PubMed ID: 12952843

Candesartan prevented nitrate tolerance and the oxidative-stress rise, preserving nitroglycerin-induced vasodilation (blood-flow effect).

PubMed ID: 14564337

Transdermal nitroglycerin (a nitrate donor) reduced inflammatory markers and increased intraplatelet cGMP in PVD patients — supports improved vascular biology and flow.

PubMed ID: 12767658

Randomized supplement trial raised serum nitrate/nitrite and prevented postprandial endothelial dysfunction — strong human evidence for improved vascular reactivity.

PubMed ID: 15589858

Estrogen markedly increased NO metabolites and improved flow-mediated vasodilation in younger women—strong support for enhanced blood flow.

PubMed ID: 15670539

Chronic nitrate therapy reduced ischemic burden in CAD, consistent with improved regional blood flow during exertion.

PubMed ID: 20585108

Direct inorganic-nitrate intervention increased plasma nitrite and cGMP with consequent BP reduction, consistent with vasodilation and improved blood flow.

PubMed ID: 22019438

Spinach (nitrate-rich) acutely raised nitrite/RXNO and improved FMD — direct evidence for enhanced endothelial-mediated blood flow.

PubMed ID: 21807659

Dark chocolate increased NOx and improved FMD in smokers — direct evidence of improved endothelial-mediated blood flow.

PubMed ID: 24286591

Hypoxic exercise raised nitrite/nitrate and improved cardiac/muscle blood flow distribution during exercise in sedentary men.

PubMed ID: 25998421

Plasma nitrate/nitrite rose substantially in diabetics — biomarker evidence of enhanced NO-mediated flow, despite no functional change.

PubMed ID: 26607938

Six weeks of beetroot juice improved endothelial function (FMD +24%) and reduced vascular stiffness and some BP measures in hypercholesterolaemia.

PubMed ID: 26037632

Single beetroot drink altered prefrontal cortex haemodynamics during tasks (task‑dependent CBF changes) and improved one cognitive measure.

PubMed ID: 28887315

Sodium nitrate increased plasma nitrite/nitrate and modestly improved exercise time in angina patients—consistent with improved perfusion.

PubMed ID: 28683960

Inorganic nitrite acutely reduced arterial stiffness and systemic vascular resistance and improved exercise hemodynamics in HFpEF—improved central/peripheral hemodynamics.

PubMed ID: 28596448

Large prospective cohort: higher vegetable-derived nitrate intake associated with lower carotid IMT and 17% lower ischemic cerebrovascular events—strong population-level evidence for cerebrovascular benefits.

PubMed ID: 29522355

8-week NaNO3 RCT in PAD patients showed significant increases in forearm blood flow—direct evidence of improved perfusion.

PubMed ID: 32866396

Acute beetroot improved flow-mediated dilation (FMD) — direct evidence of improved endothelial-dependent blood flow.

PubMed ID: 33183558

12-week nitrate supplement lowered BP and improved endothelial function in hypertensive subjects.

PubMed ID: 32758038

One-week nitrate reduced MCAv variability and BP–MCAv coherence and improved autoregulatory coupling in TIA patients.

PubMed ID: 36364742

Group-level VO2max increased (~5%), implying better systemic oxygen delivery/utilization.

PubMed ID: 35512758

Reduced VO2 for a given high-speed running workload indicates improved O2 delivery/utilization efficiency.

PubMed ID: 36839248

Improved microvascular endothelial function and better executive function (TMT-B) suggest improved cerebrovascular function/flow.

PubMed ID: 36629601

Acute improvements in central aortic pressure, subendocardial viability and microvascular perfusion in hypertensives—strong flow and perfusion effects.

PubMed ID: 36958967

Low/medium dietary nitrate over 13 weeks improved microvascular endothelial perfusion (laser Doppler) in older overweight adults.

PubMed ID: 38123239

Improved RHI and AIx after 12 weeks indicate improved endothelial function and arterial properties in COPD patients.

PubMed ID: 40209616

Large trials showed nitrate preserved FMD during systemic inflammation and increased NO biomarkers—robust endothelial protection.

PubMed ID: 28959158

Pre-workout supplement acutely increased plasma NOx ~3.5-fold and produced substantial increases in femoral artery blood flow after heavy resistance exercise.

PubMed ID: 11083193

Intravenous nicorandil improved myocardial perfusion indices in a subgroup — supports nitrate-donor benefits on blood flow.

PubMed ID: 24434794

Long-term nicorandil (nitrate donor) improved myocardial perfusion imaging and reduced cardiac death — strong evidence of improved coronary perfusion/flow.

PubMed ID: 9924848

In acute pulmonary edema patients, nitroglycerin plus NAC improved PaO2/FiO2 and oxygenation — direct evidence of improved oxygen delivery/ gas exchange.

PubMed ID: 8006274

Intermittent NTG significantly reduced perfusion defects on myocardial imaging—strong evidence of improved regional blood flow.

PubMed ID: 8087821

Improved exercise duration and less ischemia are consistent with better myocardial oxygen supply-demand balance.

PubMed ID: 9064947

Continuous IV nitroglycerin caused prompt and sustained epicardial artery dilation — strong direct evidence of increased blood flow.

PubMed ID: 9107166

Sublingual nitroglycerin improved reversible myocardial hypoperfusion on perfusion imaging.

PubMed ID: 9581727

Oral vitamin C attenuated loss of forearm blood flow response during continuous nitroglycerin, demonstrating mechanisms to preserve nitrate-mediated vasodilation.

PubMed ID: 9922856

Widespread symptomatic improvement with transdermal nitroglycerin implies improved coronary perfusion for many patients.

PubMed ID: 9583444

Small improvements in regional contraction after nicorandil reperfusion suggest improved local oxygenation.

PubMed ID: 10689845

Nicorandil (has nitrate moiety) markedly reduced intraoperative myocardial ischemia, supporting improved coronary perfusion under stress.

PubMed ID: 11557681

High‑quality trial showing increased plasma nitrite/nitrate and improved FMD after intervention — strong evidence that increasing NO metabolites improves endothelium‑dependent blood flow (relevant to nitrate biology).

PubMed ID: 11511432

Hemodynamic study: nitrates decreased systemic vascular resistance but without raising cardiac power, which is consistent with vasodilatory (flow) effects though with hemodynamic caveats.

PubMed ID: 11413083

Acute nitroglycerin infusion reduced ischemia and wall-motion abnormalities—direct evidence of improved myocardial perfusion.

PubMed ID: 11297201

Nicorandil improved LV size/function over months, consistent with favorable effects on coronary perfusion and hemodynamics.

PubMed ID: 11376307

Nicorandil reduced reperfusion-related QT dispersion during angioplasty, an electrophysiologic marker linked to reperfusion quality and blood flow.

PubMed ID: 11965271

Large nicorandil trial demonstrated fewer coronary events, implying durable vascular/flow benefits at a population level (indirect for acute flow).

PubMed ID: 12052481

Genistein increased nitrite/nitrate and improved flow-mediated vasodilation, a direct marker of improved peripheral blood flow.

PubMed ID: 12766388

Intermittent transdermal nitroglycerin decreased dipyridamole-induced ischemia, indicating improved coronary perfusion during stress.

PubMed ID: 12576956

Nicorandil prevented bronchoconstriction and preserved lung compliance under anesthesia — supports improved airway function/oxygen delivery.

PubMed ID: 15193818

Simvastatin improved flow‑mediated dilation (FMD) and reduced inflammatory markers — supports improved conduit vessel function (indirect nitrate measure).

PubMed ID: 15488877

Simvastatin ± ramipril improved endothelial function (FMD) in humans — supports improved vascular flow capacity.

PubMed ID: 15661417

Tadalafil raised nitrite/nitrate and markedly improved FMD, indicating improved endothelial-mediated blood flow.

PubMed ID: 15676171

NO‑donor improved exercise parameters and reduced ischemia, consistent with improved oxygen delivery during exertion.

PubMed ID: 15604328

Atorvastatin produced a large increase in reactive hyperaemia (endothelial response) in heart-failure patients—improvement in microvascular dilator function linked to NO pathways.

PubMed ID: 16936418

Nicorandil (a nitrate donor) reduced reperfusion injury and improved angiographic flow (cTFC) and ST resolution after MI—strong evidence of improved coronary blood flow.

PubMed ID: 16794456

High‑flavanol cocoa increased hyperemic brachial blood flow, a direct measure of improved peripheral vascular responsiveness.

PubMed ID: 17196682

Nicorandil caused measurable radial artery dilation during procedures, consistent with vasodilatory improvement in blood flow.

PubMed ID: 17879021

Systemic nicorandil in acute MI reduced MMPs and adverse remodeling, and implies preserved coronary/microvascular integrity and flow.

PubMed ID: 17967610

Intracoronary nicorandil markedly reduced no‑reflow/slow‑flow and peri‑procedural ischemic events, direct evidence of improved coronary microvascular flow.

PubMed ID: 17478142

IV nicorandil given before PCI prevented coronary microvascular impairment, supporting improved flow at the microvascular level.

PubMed ID: 19017760

Genistein improved nitrate‑mediated vasodilation in some subgroups—evidence of improved vasoreactivity relevant to blood flow.

PubMed ID: 19248104

Topical nitroglycerin improved Raynaud's patient‑reported severity (implying improved digital microvascular perfusion).

PubMed ID: 19346844

Sublingual nitroglycerin acutely dilated coronary arteries and increased number of assessable CT segments—clear acute vasodilation effect.

PubMed ID: 19406340

Intracoronary nitrate used as an endothelium‑independent vasodilator showed consistent vasodilation across stent groups—demonstrates nitrate's direct vasodilatory effect.

PubMed ID: 19276198

IV nicorandil reduced post‑PCI slow‑flow events (direct improvement in coronary blood flow).

PubMed ID: 20832994

IV nicorandil improved hemodynamics and lowered BNP/NT‑proBNP in acute heart failure.

PubMed ID: 20921442

EECP produced a ~36% NOx increase and large FMD improvements (brachial +51%, femoral +30%), strong evidence of improved endothelial-mediated flow.

PubMed ID: 20728082

Study reported improved flow‑mediated and nitrate‑mediated dilatation after treatment—direct evidence of better vasodilatory response.

PubMed ID: 20719727

Atorvastatin increased plasma nitrite/nitrate and reactive‑hyperemia NO release—supports increased NO‑mediated perfusion preoperatively.

PubMed ID: 21185507

Atorvastatin prevented GTN‑induced endothelial dysfunction and tolerance, supporting preserved NO‑mediated vascular responsiveness.

PubMed ID: 23146293

Ranolazine improved endothelium‑dependent FMD (but not nitrate‑mediated dilation), showing improved endothelial blood flow capacity.

PubMed ID: 23222003

Intracoronary nitroglycerin produced acute reductions in TIMI frame counts (improved coronary flow) — clear nitrate effect on blood flow.

PubMed ID: 23472879

Direct infusion of nitrite produced pronounced forearm vasodilation in heart-failure patients versus controls—strong, direct evidence of improved blood flow.

PubMed ID: 27179825

EECP raised NOx and improved metabolic markers — consistent increase in peripheral perfusion.

PubMed ID: 27761657

HIT increased plasma NOx and improved VO2peak/estimated perfusion — supports improved vascular function/perfusion.

PubMed ID: 26874946

Peri-procedural oral nicorandil reduced contrast‑induced kidney injury—consistent with improved renal perfusion/flow protection.

PubMed ID: 28547861

Inorganic nitrate (beetroot juice) changed aortic wave reflection and central hemodynamics in HFpEF, indicating favorable effects on arterial pulse dynamics and flow distribution.

PubMed ID: 28281738

Peri-PCI oral nicorandil greatly reduced CIN incidence in high-risk patients—supports improved microvascular/renal blood flow and perfusion.

PubMed ID: 28100342

Intracoronary nicorandil before PCI improved corrected TIMI frame count, reduced no-reflow and improved ST resolution—clear improvement in coronary blood flow.

PubMed ID: 29866368

Exercise programs improved conduit artery FMD (macrovascular flow), implying improved blood flow though not a nitrate supplementation trial.

PubMed ID: 30054187

Intravenous nicorandil preserved arterial oxygenation better than nitroglycerin during ventilation — direct oxygenation benefit.

PubMed ID: 29858919

IV nicorandil produced rapid hyperemia comparable to adenosine, demonstrating potent blood-flow increases.

PubMed ID: 29891250

Intracoronary nicorandil during PCI improved myocardial perfusion and microvascular perfusion grades — strong blood-flow benefit.

PubMed ID: 31203378

Local GLP‑1 analogues increased skin microvascular perfusion and endothelial nitrate production — relevant to improved microcirculatory flow.

PubMed ID: 30821716

Post-MI nicorandil reduced infarct size and improved LVEF—consistent with better myocardial oxygen supply/utilization.

PubMed ID: 31385178

Higher peri-procedural nicorandil dosing reduced CIN rates, implying better renal perfusion during stress.

PubMed ID: 32694343

Aerobic training increased NOx and improved FMD—markers of improved endothelial-mediated blood flow.

PubMed ID: 32154613

High-dose atorvastatin increased NO and improved endothelial measures in leukoaraiosis patients—indicative of improved cerebral microvascular function.

PubMed ID: 33847683

Intracoronary nicorandil produced quantitative improvements in myocardial perfusion and TIMI frame counts—direct evidence of better blood flow.

PubMed ID: 34732357

Danhong injection study reported angina/ perfusion benefits at 28 days (though indirect to nitrate biology), but perfusion effects are present.

PubMed ID: 34871513

Intracoronary nicorandil attenuated inflammation/oxidative stress and is a vasodilator—supports improved microvascular flow.

PubMed ID: 34391687

IV nicorandil improved diastolic indices and LVEF, consistent with better cardiac perfusion/flow.

PubMed ID: 35933413

Evolocumab+empagliflozin improved FMD and increased nitrate/nitrite—mechanistic evidence of better endothelial‑mediated flow.

PubMed ID: 35258101

Sublingual nitroglycerin produced predictable transient BP fall and vasodilation—demonstrates rapid increases in regional blood flow.

PubMed ID: 36073634

IV nicorandil (nitrate donor) before PCI reduced microvascular obstruction and infarct size—strong microvascular flow benefit.

PubMed ID: 37875733

Intra‑arterial nitroglycerin raised NOx in the cerebral/arterial setting with non‑significant trends toward smaller infarcts and better outcomes—most direct stroke/brain signal.

PubMed ID: 29659585

IV nicorandil reduced periprocedural myocardial injury—consistent with improved microvascular protection and vessel function in procedural settings.

PubMed ID: 28617765

Nicorandil reduced no‑reflow, oxidative markers and improved LVEF—strong vascular/microvascular protection evidence.

PubMed ID: 17346816

Peri‑PCI nicorandil suppressed enzyme rises and improved wall motion—supports vascular/myocardial protection.

PubMed ID: 16337497

IV nicorandil around stenting reduced biomarker evidence of myocardial injury, consistent with vascular protection.

PubMed ID: 11444499

Perioperative nicorandil reduced biochemical myocardial injury markers and improved immediate cardiac recovery—indicative of protective vascular effects.

PubMed ID: 10714017

Nicorandil pretreatment reduced postoperative cardiac enzymes, implying myocardial (microvascular) protection.

PubMed ID: 10618560

IV nitroglycerin after stenting reduced minor myocardial necrosis, indicating improved local vascular outcomes.

PubMed ID: 27488183

Dietary root juice raised nitrite and reduced platelet aggregation—changes consistent with vascular health benefits (improved endothelial/antithrombotic profile).

PubMed ID: 18250365

Dietary nitrate (beetroot) raised NOx and lowered BP and platelet aggregation, markers of vascular health.

PubMed ID: 32326664

Ubiquinol caused dose-dependent increases in NOx and FMD, indicating improved endothelial function.

PubMed ID: 32683790

Citrulline in T2D increased NOx and improved antioxidant markers; supports vascular health indirectly.

PubMed ID: 16446007

Oral propionyl-L-carnitine improved ABI and walking distance in diabetics — clinically meaningful vascular improvement.

PubMed ID: 30701736

Pre‑PCI nicorandil (NO donor) reduced troponin release, implying reduced ischemic injury and vasoprotective effects.

PubMed ID: 8483018

Review indicates long‑acting nitrates can increase arterial compliance and selectively reduce systolic pressure — markers of vascular health.

PubMed ID: 8370370

Nicorandil (nitrate donor) reduced angina and improved exercise capacity, consistent with beneficial vascular actions in clinical use.

PubMed ID: 32729923

Sustained ambulatory BP lowering and increased plasma nitrate over 60 days indicates meaningful improvement in vascular health markers.

PubMed ID: 24457276

Nicorandil decreased microvascular resistance and troponin release after PCI — supports vascular protection at the microvascular level.

PubMed ID: 25174952

Peri-procedural nicorandil reduced myocardial injury and improved LVEF at 6 months, consistent with vascular/myocardial protection.

PubMed ID: 15901241

Nicorandil prevented procedure-induced platelet and neutrophil activation, supporting vascular protection at the microvascular level.

PubMed ID: 16116055

Large RCT: IV nicorandil improved epicardial/microvascular reperfusion and reduced death/heart-failure events—strong vascular-health evidence.

PubMed ID: 15459610

IV nicorandil suppressed ROS surge and reduced no-reflow, with improved LV function at 6 months—vascular protective effects.

PubMed ID: 19033012

Zofenopril improved carotid IMT and NO/oxidative biomarkers over long term; supports vessel health via NO pathways (drug-specific evidence).

PubMed ID: 12419572

Acute oral L-arginine significantly improved flow‑mediated (endothelium-dependent) dilation — marker of endothelial health.

PubMed ID: 12189442

Acute L-arginine infusion increased NO and antioxidant markers and lowered homocysteine — changes consistent with endothelial benefit.

PubMed ID: 9809945

Restored NO biomarkers and improved walking distances suggest functional vascular improvement in peripheral arteries.

PubMed ID: 9799202

ADMA elevation associated with endothelial dysfunction and reversible with L‑arginine—strong mechanistic linkage to NO‑dependent vascular health.

PubMed ID: 8627976

Dose-dependent coronary dilation demonstrates direct vasomotor effects on coronary arteries.

PubMed ID: 16936418

Nicorandil reduced reperfusion injury and improved perfusion after MI—supports healthier coronary microvasculature after ischemic injury.

PubMed ID: 1442478

Marked reduction in infarct size with ISDN in non‑reperfused MI implies vascular/tissue protective effects.

PubMed ID: 15604328

Atorvastatin markedly increased reactive hyperaemia percentage (endothelial function) in heart-failure patients—supports improved vascular health (NO-related pathways).

PubMed ID: 16330680

Long-term low-saturated-fat dietary intervention improved flow-mediated dilation in boys at age 11, indicating healthier conduit vessel function.

PubMed ID: 15661417

Tadalafil raised nitrite/nitrate and markedly improved FMD — direct evidence of improved endothelial function and vessel health.

PubMed ID: 15547020

Nicorandil (NO donor) reduced major cardiac events vs placebo in a large trial — consistent with improved vascular outcomes.

PubMed ID: 15488877

Simvastatin ± ramipril improved FMD and reduced oxidative markers; supports healthier conduit vessels (indirect nitrate relevance).

PubMed ID: 15193818

Simvastatin improved flow‑mediated dilation (FMD) and lowered inflammatory markers; plasma nitrate measured though unchanged — supports improved vascular health.

PubMed ID: 14714578

ARBs/ACE inhibitor increases in urinary NOx correlated with proteinuria improvement — systemic NOx changes linked with vascular/renal benefit.

PubMed ID: 12766388

Intermittent nitroglycerin produced reproducible anti-ischaemic effects; repeated beneficial effects on ischemia support vessel functional health.

PubMed ID: 12052481

Genistein increased NO metabolites markedly and improved flow-mediated vasodilation, indicating improved endothelial health (biomarker + functional evidence).

PubMed ID: 11965271

Large randomized trial showed nicorandil reduced major coronary events, a strong clinical signal of vascular benefit/health over time.

PubMed ID: 12050277

Vitamin E increased circulating NO products and decreased sVCAM-1 in hypercholesterolemic subjects, supporting endothelial benefit (biomarker evidence).

PubMed ID: 12361204

Atorvastatin increased NO metabolites and lowered an endothelial activation marker, indirectly supporting improved vascular health.

PubMed ID: 11297201

Nicorandil improved LV remodeling and function over 6 months, consistent with favorable cardiovascular remodeling and vascular/ventricular interaction benefits.

PubMed ID: 11557681

Randomized trial showed increased NO metabolites and improved flow‑mediated dilation — robust evidence for improved endothelial function/vascular health via NO pathway modulation.

PubMed ID: 9581727

Oral vitamin C attenuated loss of vasodilator response and cGMP during continuous nitroglycerin—mechanistic support for maintained vascular function.

PubMed ID: 9610531

Intermittent transdermal nitroglycerin prevented LV dilation after MI—evidence of favorable cardiac remodeling and vascular/hemodynamic benefit in some subgroups.

PubMed ID: 9355892

Vitamin E prevented decline in nitroglycerin‑induced vasodilation and platelet cGMP — preserving endothelial responsiveness.

PubMed ID: 9064947

Continuous NTG caused durable epicardial dilation and neurohormonal changes consistent with vascular effects.

PubMed ID: 17879021

Nicorandil reduced MMP‑2/9 and attenuated adverse LV remodeling after MI, strong evidence of vascular/cardiac tissue protection.

PubMed ID: 17967610

Continuous intracoronary nicorandil reduced no‑reflow/MI during atherectomy vs verapamil—direct vascular protective effect.

PubMed ID: 17478142

IV nicorandil before PCI prevented coronary microvascular impairment and improved long‑term cardiac event rates, indicating vascular protection.

PubMed ID: 19017760

Genistein improved nitrate‑mediated vasodilation (endothelium‑independent) and metabolic markers in some subgroups—evidence of improved vascular responsiveness.

PubMed ID: 19346844

Intravenous/sublingual nitroglycerin produced predictable coronary dilation and improved imaging assessability—demonstrates preserved vasodilatory capacity to nitrate challenge.

PubMed ID: 19276198

IV nicorandil reduced slow‑flow and repeat revascularization after PCI, indicating improved coronary vascular outcomes.

PubMed ID: 20921442

EECP produced significant increases in plasma NOx, large improvements in brachial/femoral FMD and reduced ET‑1—strong vascular health signal.

PubMed ID: 20728082

Improved flow‑mediated and nitrate‑mediated dilatation indicate better endothelial and smooth‑muscle vessel function.

PubMed ID: 20719727

Atorvastatin raised plasma NO metabolites and reactive hyperemia NO release preop—consistent with enhanced NO biology and vascular health.

PubMed ID: 21185507

Atorvastatin prevented GTN‑induced endothelial dysfunction and tolerance—preservation of endothelial responsiveness suggests vascular benefit.

PubMed ID: 23146293

Ranolazine improved endothelial (FMD) function in diabetics—evidence for improved endothelial health.

PubMed ID: 23472879

Infused nitrite caused pronounced vasodilation in CHF patients and revealed altered nitrite kinetics—evidence of direct vascular action of nitrite/nitrate biology.

PubMed ID: 27761657

HIT raised EPCs and plasma NOx and improved VO2peak — supports vascular repair/function improvements.

PubMed ID: 28709700

Prasugrel increased nitrite and improved FMD (endothelial function), indirectly supporting vascular health via NO pathways.

PubMed ID: 28547861

Inorganic nitrate (beetroot) acutely improved aortic wave reflections and central pulse dynamics in HFpEF—direct mechanistic evidence of beneficial arterial effects.

PubMed ID: 28100342

Peri-PCI nicorandil improved reperfusion and reduced no‑reflow—favors vascular protection in the coronary circulation.

PubMed ID: 29866368

Exercise improved conduit artery FMD (macrovascular endothelial health) in metabolic syndrome subjects — relevant to vessel health.

PubMed ID: 29891250

Intracoronary nicorandil improved myocardial perfusion, TMPG and ST-resolution and reduced 6-month MACEs — demonstrates vascular/microvascular benefit.

PubMed ID: 31639790

Nicorandil peri-procedurally reduced contrast-induced nephropathy and improved renal markers — suggests protective vascular/organ effects.

PubMed ID: 30987432

Nicorandil reduced contrast-induced nephropathy after PCI, indicative of protective vascular/renal effects.

PubMed ID: 30821716

Post-STEMI nicorandil reduced infarct size and improved LVEF—favorable markers for vascular/myocardial health.

PubMed ID: 31385178

Dose-dependent protection from CIN by nicorandil suggests reproducible vascular/renal protective effects.

PubMed ID: 32694343

Aerobic training increased NOx and FMD—direct evidence of improved endothelial/vascular health via NO pathway.

PubMed ID: 32154613

Atorvastatin increased NO measures and RHI in leukoaraiosis patients—indicative of improved endothelial function.

PubMed ID: 32524226

Intermittent hypoxia raised NOx and lowered systolic BP—supports vascular adaptations mediated by NO.

PubMed ID: 31658134

Oral nicorandil peri-PCI lowered CIN incidence—consistent with vascular protection.

PubMed ID: 33847683

Intracoronary nicorandil produced quantitatively better myocardial perfusion and TIMI frame counts—strong vascular benefit.

PubMed ID: 34871513

Nicorandil attenuated PCI-related inflammation and oxidative stress—mechanisms that protect vessels.

PubMed ID: 34738551

IV nicorandil improved cardiac/renal biomarkers—strong cardio-renal and vascular benefit in cardiorenal syndrome.

PubMed ID: 33547969

RIC increased NOx and reduced oxidative stress with favorable LV remodeling—supports vascular and myocardial protection.

PubMed ID: 34391687

IV nicorandil in acute heart failure improved cardiac indices and biomarkers, indicating vascular/functional cardiac benefit.

PubMed ID: 35647186

Nicorandil added to aspirin improved ischemia metrics and echocardiographic measures—consistent with vascular benefit.

PubMed ID: 36342289

Concentrated beetroot juice lowered key inflammatory markers in T2DM—supports healthier vascular inflammatory milieu and NO-pathway engagement.

PubMed ID: 35933413

Evolocumab added to empagliflozin improved FMD and increased NO metabolites—evidence for improved endothelial health.

PubMed ID: 35820510

Aerobic training increased NOx and decreased central arterial stiffness—markers of healthier vessels.

PubMed ID: 36073634

IV nicorandil reduced infarct size and MVO—demonstrates vascular microcirculatory protection by a nitrate donor.

PubMed ID: 37634247

Nicorandil attenuated post‑angiography renal decline—consistent with improved organ microvascular function.

PubMed ID: 36881267

Oral nicorandil reduced contrast‑induced kidney injury—consistent with vascular protection in vulnerable organs.

PubMed ID: 38411168

Peri‑procedural nicorandil reduced CIN incidence—supports vascular/endothelial protective effect.

PubMed ID: 40431357

Removing nitrite additives lowered urinary nitrate and improved oxidized‑LDL and inflammatory markers — supports better vascular health associated with dietary nitrate exposure changes.

PubMed ID: 9875113

Quantified coronary vasodilation with ISDN/GTN demonstrates preserved conduit vessel responsiveness — supports vascular health/vasoreactivity.

PubMed ID: 9809925

Carvedilol prevented development of nitrate tolerance and preserved forearm blood flow and platelet cGMP responses — supports maintenance of vascular responsiveness (healthier vessel function).

PubMed ID: 15791442

Nicorandil improved imaging markers and remodeling after AMI versus ISDN — supportive of vascular/cardiac structural benefit.

PubMed ID: 14729792

Improved coronary microcirculation and ST recovery with nicorandil after AMI suggests beneficial vascular effects.

PubMed ID: 16169327

Nicorandil improved sympathetic innervation imaging and LVEF in ischemic cardiomyopathy — consistent with improved vascular/vascular‑nerve interactions.

PubMed ID: 15965356

Long‑term nicorandil improved flow‑mediated dilation and prevented carotid IMT progression versus isosorbide dinitrate — strong vascular health signal.

PubMed ID: 17641250

Nitrate exposure (PETN/GTN) protected against ischemia–reperfusion endothelial dysfunction, indicating preservation of endothelial health.

PubMed ID: 19262229

Nicorandil reduced proteinuria and urinary endothelin-1, suggesting protective vascular/renal endothelial effects.

PubMed ID: 21240870

Long-term ISMN reduced LV mass and acute HF events in dialysis patients — clinical evidence of cardiovascular structural/functional benefit.

PubMed ID: 20812862

PETN increased circulating endothelial progenitor cells and enhanced EPC function while avoiding endothelial impairment, supporting vascular repair/health.

PubMed ID: 22298019

PETN preserved endothelial function after ischemia better than GTN, indicating a vascular-protective organic-nitrate effect.

PubMed ID: 23296279

Chronic oral nitrates in CAPD patients produced marked LV mass regression, BP reductions and decreased ADMA—strong vascular remodeling and endothelial‑pathway evidence.

PubMed ID: 23806384

Dietary/inorganic nitrate increased platelet cGMP and had modest antiplatelet effects in men, consistent with vascular benefit.

PubMed ID: 28100019

HVPG‑guided therapy including nitrates reduced rebleeding and mortality and produced greater HVPG reductions—clinically meaningful vascular strategy benefit.

PubMed ID: 30054906

Peri‑procedural isosorbide dinitrate reduced contrast‑induced kidney injury and adverse events—clinical evidence of vascular/end‑organ protection.

PubMed ID: 40123490

Isosorbide mononitrate associated with lower radial artery graft failure vs diltiazem, implying improved vascular conduit health.

PubMed ID: 27600061

Long‑term Mediterranean diet raised plasma nitrate and antioxidant enzymes while lowering xanthine oxidase — supportive of improved vascular antioxidant status and vessel health.

PubMed ID: 24434794

Long-term oral nicorandil (nitrate donor) reduced cardiac deaths and improved myocardial metabolic imaging — strong clinical vascular benefit from nitrate-donor therapy in this population.

PubMed ID: 11083193

IV nicorandil improved myocardial perfusion metrics in a subgroup — supports vascular perfusion benefits of nitrate-donor therapy.

PubMed ID: 40209616

Large trials showed nitrate preserved FMD during inflammation, increased NO biomarkers, and shifted cytokines—strong vascular protection evidence.

PubMed ID: 38123239

12-week BRJ improved RHI, AIx and reduced home SBP—robust improvements in arterial/endothelial health in COPD.

PubMed ID: 38513060

Large RCT showed major reductions in CIN and downstream cardiac/kidney events after short‑course inorganic nitrate—strong clinical vascular/organ protection signal.

PubMed ID: 36958967

13‑week nitrate supplementation improved clinic SBP and microvascular perfusion—consistent with improved small‑vessel vascular health.

PubMed ID: 36629601

Improvements in central aortic pressure, RVSE and microvascular reactivity in hypertensives support vascular health benefits.

PubMed ID: 33982797

Six-month beetroot juice reduced carotid intima-media thickness (CIMT), a direct structural surrogate of vascular health—strong evidence for vessel benefit.

PubMed ID: 34236392

12-week high-nitrate vegetable intake modestly lowered daytime SBP—blood pressure improvements support vascular health.

PubMed ID: 32758038

Reduced BP variability and improved cerebral autoregulation suggest vascular stabilization post-nitrate.

PubMed ID: 33183558

12-week nitrate supplement produced sustained BP reduction and improved endothelial function in hypertensives.

PubMed ID: 32866396

Acute FMD improvement is direct evidence of improved endothelial vascular health.

PubMed ID: 29522355

Longer-term NaNO3 in PAD improved regional blood flow and exercise pressor responses—evidence of improved peripheral vascular function.

PubMed ID: 30294825

Six months of beetroot juice decreased LV volumes and changed geometry, indicating favorable long-term cardiovascular remodeling independent of BP.

PubMed ID: 28596448

Large prospective study linking higher vegetable nitrate intake to lower carotid IMT and fewer ischemic cerebrovascular events—strong observational evidence for vascular health.

PubMed ID: 28683960

Acute inorganic nitrite reduced arterial stiffness and improved arterial compliance and wave reflections—direct mechanistic evidence of vascular benefit.

PubMed ID: 25421976

4‑week RCT in hypertensives: sustained lower ambulatory SBP/DBP with concordant increases in plasma nitrite and cGMP—supports vascular health improvement.

PubMed ID: 26607938

6‑week RCT: beetroot juice improved endothelial function (FMD +24%) and reduced vascular stiffness—robust evidence for vascular health benefit.

PubMed ID: 21807659

Dark chocolate increased NOx and improved endothelial function (FMD) in smokers, supporting vascular health via NO pathways.

PubMed ID: 22019438

Acute nitrate-rich spinach meaningfully increased nitrite/RXNO and improved FMD — strong endothelial benefit.

PubMed ID: 20585108

Inorganic nitrate raised plasma nitrite/cGMP and lowered BP, indicating improved endothelial/vascular function.

PubMed ID: 15589858

Estrogen treatment greatly increased NO metabolites and improved flow-mediated vasodilation in younger women—strong vascular benefit signal.

PubMed ID: 12767658

Supplementation increased serum nitrate/nitrite and prevented meal-induced endothelial dysfunction — good human evidence supporting vascular health effects.

PubMed ID: 14564337

Transdermal nitroglycerin reduced inflammatory markers and increased intraplatelet cGMP in PVD patients — supports vascular health benefits of nitrate donors.

PubMed ID: 12952843

Candesartan prevented development of nitrate tolerance and oxidative-stress marker rises, protecting NO-mediated endothelial responses.

PubMed ID: 12727580

Genistein RCT produced a quantified nitrate rise and improved flow-mediated vasodilation — supports improved endothelial health.

PubMed ID: 10728365

Growth hormone raised urinary nitrate and cGMP in cardiomyopathy patients — indicative of increased NO activity and vascular effects.

PubMed ID: 9557281

Vitamin E prevented development of nitrate tolerance to nitroglycerin, preserving vasodilator response and platelet cGMP.

PubMed ID: 7921519

Oral nicorandil lowered BP without impairing renal flow—favorable vascular hemodynamic profile.

PubMed ID: 29726480

Intracoronary nicorandil improved reperfusion and early LVEF with less hypotension—vascular protective in acute setting.

PubMed ID: 30174413

Peri‑procedural oral nicorandil lowered myocardial injury biomarkers—supports vessel/protection effects in coronary context.

PubMed ID: 24071762

PETN improved total exercise duration and angina-related endpoints in symptomatic/refractory subgroup, reflecting improved exercise tolerance in that group.

PubMed ID: 17526976

Large trial: nicorandil improved angina attack frequency and nitroglycerin use and prolonged exercise parameters vs baseline (superior clinical benefit vs ISMN in some measures).

PubMed ID: 16353064

Crossover showed long‑acting ISMN gave longer‑lasting relief and better exercise outcomes than ISDN in stable angina.

PubMed ID: 16169327

Nicorandil improved sympathetic imaging markers and LVEF over 6 months in ischemic cardiomyopathy, consistent with better exercise capacity.

PubMed ID: 14729792

In AMI patients nicorandil improved ST recovery, coronary flow and later wall motion compared with ISDN — supports improved functional recovery and tolerance.

PubMed ID: 12515103

ISMN added to atenolol produced modest objective improvement in ischaemic threshold and angina.

PubMed ID: 12362508

Demonstrated acute benefit on exercise times and showed tolerance with continuous dosing — intermittent use preserved tolerance.

PubMed ID: 11740135

ISMN improved total exercise time in elderly stable angina patients, though less than amlodipine.

PubMed ID: 11208406

Clear, dose- and schedule-dependent improvements in walking time to ischemia and longer-term exercise tolerance.

PubMed ID: 11072531

Demonstrated that once-daily dosing preserved walking-time to ischemia vs 4×daily dosing which induced tolerance — clear exercise-tolerance signal.

PubMed ID: 10549836

12-hour ISDN dosing improved brachial dilation and treadmill ischemia time where 6-hour dosing did not — demonstrates improved exercise tolerance with regimen that avoids tolerance.

PubMed ID: 10393392

Randomized trial showed small overall increases in exercise time in HF; clearer benefit in a prespecified EF subgroup — direct evidence for improved tolerance.

PubMed ID: 9830234

Controlled‑release 5‑ISMN clearly improved exercise duration and times to ischemia/chest pain — strong evidence for improved tolerance.

PubMed ID: 9068264

ISDN increased pain‑free and maximal walking distance and lowered femoral resistance in PAD — direct improvement in exercise tolerance.

PubMed ID: 8659199

ISDN reduced femoral vascular resistance and preserved walking ability in PAD patients (supporting exercise tolerance).

PubMed ID: 7638969

SR isosorbide-5-MN significantly prolonged time to 1 mm ST depression on exercise testing — direct evidence of improved exercise tolerance.

PubMed ID: 7788038

Reduced ischemic perfusion defect on stress imaging implies better tolerance of exertion.

PubMed ID: 7866603

ISDN markedly reduced exercise‑induced ischemia and improved exercise endpoints vs captopril.

PubMed ID: 8370371

Nicorandil and atenolol produced similar ~1.3–1.5 min increases in time to peak exercise.

PubMed ID: 8256699

Large randomized trial showing consistent increases in total exercise time with extended‑release ISMN.

PubMed ID: 1530423

Once‑daily SR ISDN produced similar ergometric benefit to TID dosing in randomized comparison.

PubMed ID: 1754868

Large RCT: IS-5-MN significantly improved total exercise time, time to angina and 1 mm ST depression—robust evidence for improved exercise tolerance.

PubMed ID: 2144705

Nicorandil increased predose and postdose exercise time significantly vs baseline—strong direct evidence of improved exercise tolerance.

PubMed ID: 2129317

Chronic long-acting nitrate therapy reduced pulmonary filling pressures and improved angina symptoms/ischemia—translates to better exercise tolerance.

PubMed ID: 1282180

Study comparing nicorandil and nitrates showed similar increases in exercise capacity across arms.

PubMed ID: 38430173

Nicorandil (a nitrate donor) improved angina symptoms and cardiac function in stable angina patients, consistent with enhanced exercise tolerance in cardiac populations.

PubMed ID: 34391687

IV nicorandil in acute heart failure improved symptoms and LVEF, which is likely to improve exercise tolerance in these patients.

PubMed ID: 30821716

Oral nicorandil after STEMI reduced infarct size and improved LVEF—physiologic improvements that support exercise tolerance.

PubMed ID: 27761657

HIT raised NOx, EPCs and led to greater VO2peak and estimated peak cardiac output compared with moderate training.

PubMed ID: 26884620

IV nicorandil improved dyspnea and diastolic filling rapidly in acute HF, translating to better exertional tolerance.

PubMed ID: 25701829

Nicorandil provided better angina relief and symptom class improvements than nitroglycerin — supports improved exertional tolerance in angina patients.

PubMed ID: 24650926

Aortic waveform-guided therapy (more frequent nitrate initiation) showed a clinically meaningful VO2 increase.

PubMed ID: 23472879

Infused nitrite caused marked increases in forearm blood flow in CHF patients—direct physiological evidence that nitrite can improve peripheral perfusion and therefore exercise tolerance potential.

PubMed ID: 23222003

Intracoronary nitroglycerin acutely improved coronary flow — a mechanistic basis for improved cardiac exercise tolerance.

PubMed ID: 20921442

EECP increased NOx, improved FMD, and improved angina/exercise capacity in controlled trial.

PubMed ID: 15662290

Trimetazidine treatment produced marked increases in exercise test duration in patients (many on nitrates), indicating improved tolerance in a cardiac population.

PubMed ID: 15676171

Large randomized molsidomine trials demonstrated improved exercise-test parameters and fewer angina episodes — strong direct evidence.

PubMed ID: 12576956

IV nicorandil prevented fentanyl‑associated bronchoconstriction and loss of compliance intra‑operatively → better airway mechanics that could support exercise tolerance.

PubMed ID: 12766388

Intermittent transdermal nitroglycerin produced clear anti-ischaemic effects during stress testing—direct evidence for improved ischemic exercise tolerance.

PubMed ID: 11297201

Six-month nicorandil therapy improved LV volumes and EF, implying better cardiac performance and exercise tolerance over time.

PubMed ID: 11413083

NTG infusion 24 h before angioplasty reduced ischemic responses during a controlled ischemic stress—strong direct cardioprotective/anti-ischaemic signal.

PubMed ID: 10689845

Nicorandil substantially reduced intraoperative ischemia; while not an exercise study, this demonstrates anti‑ischemic properties that can translate to exercise tolerance in ischemia‑prone tissues.

PubMed ID: 9922856

Large open-label program reported fewer angina episodes and more pain-free patients—consistent with improved exercise tolerance.

PubMed ID: 9610531

Intermittent transdermal nitroglycerin prevented LV dilation, particularly in low-EF patients — likely to improve functional capacity.

PubMed ID: 8087821

Transdermal nitroglycerin regimens produced large, clinically meaningful increases in maximum exercise duration and reduction in angina episodes.

PubMed ID: 8006274

Intermittent NTG patches reduced ischemic perfusion defects on imaging without changes in workload — supports improved ischemic tolerance to exercise.

PubMed ID: 1282179

Nicorandil and nifedipine increased exercise duration/time to ischemia in stable angina patients.

PubMed ID: 1927943

Randomized trial showing increased exercise duration and delayed ischemic ECG changes with transdermal nitroglycerin—direct evidence of improved exercise tolerance.

PubMed ID: 1909152

Intermittent/titrated transdermal NTG avoided tolerance and modestly improved exercise performance versus continuous dosing.

PubMed ID: 24434794

Long-term nicorandil improved myocardial metabolism and clinical outcomes; could relate to preserved exercise capacity in cardiac patients.

PubMed ID: 38123239

COPD RCT showed clinically meaningful increases in 6MWD and improved vascular markers—clear improved tolerance for exertion.

PubMed ID: 35512758

One-week beetroot improved high-speed running economy and increased cycling time-to-exhaustion in trained athletes—strong endurance signal.

PubMed ID: 36364742

VO2max gains in T2DM imply improved physiological capacity/tolerance for exercise.

PubMed ID: 32376732

COPD pulmonary rehab RCT increased ISWT distance (~+30 m) — clear improvement in exercise tolerance/capacity.

PubMed ID: 29522355

Eight weeks NaNO3 in PAD increased forearm blood flow and lowered pressor responses during exercise, consistent with better exercise tolerance.

PubMed ID: 28887315

Oral sodium nitrate modestly increased total exercise time in patients with chronic angina (randomized crossover), a direct measure of tolerance.

PubMed ID: 27777094

Small but consistent sprint and Yo‑Yo improvements indicate better sustained intermittent performance.

PubMed ID: 24286591

Hypoxic exercise increased nitrite/nitrate and improved Q(M)/Q(H) (muscle perfusion) and progenitor cells, consistent with better exercise tolerance in sedentary men.

PubMed ID: 19276981

Cardiac rehab participants showed increased plasma nitrates and cardiorespiratory capacity, a direct clinical signal of improved exercise tolerance.

PubMed ID: 15670539

In men with CAD, nitrates reduced ischemic episodes during exertion — direct evidence of improved tolerance to physical activity in patients.

PubMed ID: 28617765

Nicorandil improved microvascular reperfusion post‑PCI—cardiac example of improved tissue tolerance to ischemia.

PubMed ID: 40733006

Attenuation of post‑match performance drops indicates improved tolerance to repeated/high load activity.

PubMed ID: 35010917

9‑week randomized trial showed increased estimated VO2max (Cooper) in citrulline + nitrate group — strong support for increased capacity.

PubMed ID: 16446007

Oral propionyl-L-carnitine substantially increased pain-free walking distance — strong exercise-tolerance evidence.

PubMed ID: 8181883

Double‑blind crossover: intermittent transdermal nitrate significantly increased time to angina, time to ST depression and total exercise duration.

PubMed ID: 8370370

Nicorandil reduced angina and increased maximum exercise capacity in a 3‑month randomized trial.

PubMed ID: 1282609

Pre‑treatment with nitrates reduced post‑ischaemic myocardial stunning after angioplasty, reflecting preserved post‑ischemic exercise function.

PubMed ID: 1350882

Intermittent transdermal nitrate reduced ambulatory ischemia over 12 weeks vs continuous use (preserved exercise/ischemic benefit).

PubMed ID: 29976553

Larger improvements in claudication onset time and 6MW distance indicate better exercise tolerance in PAD.

PubMed ID: 28327503

Six days of beetroot juice increased Yo-Yo IR1 distance (+3.4%) in trained soccer players, indicating better intermittent endurance.

PubMed ID: 19922034

Exercise program increased peak VO2 in overweight children — direct capacity improvement (NO markers unchanged).

PubMed ID: 9809945

Randomized trial in intermittent claudication showed large increases in pain-free and absolute walking distance — direct evidence of improved exercise tolerance.

PubMed ID: 23338814

Sublingual nitrates significantly increased time to 1 mm ST‑depression (exercise ischemia) in obstructive CAD patients—direct evidence of improved exercise tolerance.

PubMed ID: 23806384

Dietary/inorganic nitrate reliably raises nitrite (mechanism relevant to endurance), though this study focused on platelet effects rather than performance.

PubMed ID: 1442478

Marked reduction in infarct size in non‑reperfused MI implies tissue resilience/protection.

PubMed ID: 1754868

IS-5-MN improved exercise performance and reduced anginal episodes across multiple patients—translates to greater resilience to exertional ischemia.

PubMed ID: 38411168

Peri‑procedural nicorandil reduced CIN incidence in elective PCI—demonstrates organ resilience benefit from nitrate donor.

PubMed ID: 36881267

Oral nicorandil around catheterization significantly reduced contrast‑induced nephropathy—clinical organ protection/resilience.

PubMed ID: 37634247

Nicorandil or atorvastatin plus hydration attenuated renal function decline after contrast—protective effect.

PubMed ID: 36073634

IV nicorandil reduced infarct size and MVO in STEMI—improved myocardial resilience to ischemia.

PubMed ID: 33547969

Remote ischemic conditioning raised NOx and associated with favorable LV remodeling—supports system-level resilience via NO pathways.

PubMed ID: 34738551

IV nicorandil in cardiorenal syndrome rapidly improved LVEF and renal markers, indicating stronger cardio-renal resilience.

PubMed ID: 31639790

Peri-procedural nicorandil lowered contrast-induced nephropathy incidence, indicating organ-protective resilience.

PubMed ID: 29891250

Intracoronary nicorandil reduced adverse events at 6 months after STEMI — suggests improved cardiac resilience/recovery.

PubMed ID: 15676171

Improved exercise tolerance and reduced ischemic episodes with an NO donor may translate to greater resilience to physical stress.

PubMed ID: 11965271

Nicorandil reduced major coronary events in a large trial, indicating improved long-term cardiovascular resilience.

PubMed ID: 9064947

Persistent epicardial dilation and neurohormonal changes could support resilience to ischemic stress.

PubMed ID: 8087821

Marked improvement in exercise tolerance and near elimination of angina episodes indicates improved resilience to physical stress in cardiac patients.

PubMed ID: 40209616

Preservation of endothelial function under inflammatory stress and faster lesion resolution imply improved physiological resilience.

PubMed ID: 38123239

COPD patients showed durable improvements in BP, vascular markers and walking distance—greater day-to-day resilience.

PubMed ID: 38513060

Large RCT: 5‑day oral inorganic nitrate before angiography dramatically reduced contrast‑induced nephropathy and 1‑year MACE/MAKE—clear enhancement of organ/system resilience.

PubMed ID: 36629601

Improvements in central hemodynamics and microvascular reactivity in hypertensives reflect greater cardiovascular resilience.

PubMed ID: 32376732

Improved functional walking distance and lower systolic BP in COPD during rehab indicate enhanced resilience to exertion in patients.

PubMed ID: 32718702

Intraoperative NO halved AKI rates and improved urine biomarkers/output, indicating organ resilience under stress.

PubMed ID: 30294825

Six months of dietary nitrate reduced LV volumes and altered cardiac geometry—structural adaptations that could contribute to greater cardiovascular resilience.

PubMed ID: 28596448

Higher habitual vegetable nitrate intake associated with lower carotid IMT and fewer ischemic events, suggesting long-term vascular resilience.

PubMed ID: 9452157

Observational AMI cohort: nitrate-treated patients had lower 7-day mortality — suggests short-term clinical resilience.

PubMed ID: 29726480

Intracoronary nicorandil lowered reperfusion failure and improved early LVEF, consistent with organ resilience.

PubMed ID: 28617765

Nicorandil before angioplasty reduced no‑reflow and oxidative injury, indicating improved myocardial resilience to ischemia.

PubMed ID: 16337497

IV nicorandil reduced peri‑procedural enzyme elevations, reflecting protection against procedural injury.

PubMed ID: 40733006

Sustained performance across matches and preserved anaerobic power indicate improved resilience to repeated exertion.

PubMed ID: 35010917

9‑week improvements in VO2max and some power metrics support greater capacity to tolerate training load.

PubMed ID: 8181883

Intermittent nitrates improved exercise duration and delayed ischemia — supports resilience to exertional ischemia in cardiac patients.

PubMed ID: 1282609

Nitrate pre‑treatment reduced myocardial stunning after ischemia, implying better resilience to ischemic insult.

PubMed ID: 29976553

Functional improvements in PAD suggest enhanced resilience of the limb to repeated exertion.

PubMed ID: 16116055

Nicorandil given before reperfusion reduced death/heart-failure rehospitalization—evidence of improved cardiovascular resilience to ischemic insult.

PubMed ID: 11804989

Nicorandil restored ischemic preconditioning in elderly, suggesting enhanced resilience to ischemic insult.

PubMed ID: 11573520

Prophylactic nicorandil reduced intra-op ischemia and MIs, indicating improved tolerance to ischemic stress (resilience).

PubMed ID: 10080465

Nicorandil reduced adverse outcomes after MI indicating improved organ-level resilience.

PubMed ID: 9809945

Marked walking-distance gains in claudication reflect improved resilience of limb function under stress.

PubMed ID: 30054906

Peri‑procedural nitrate reduced contrast nephropathy and adverse events, indicating organ protection under stress.

PubMed ID: 28100019

HVPG‑guided strategy using nitrates (where indicated) reduced rebleeding and mortality—clinical resilience in portal hypertension management.

PubMed ID: 23296279

Long‑term oral nitrates produced LV mass regression and lower antihypertensive needs in dialysis patients—improved cardiac/vascular resilience.

PubMed ID: 15731536

Lower peri‑procedural myocardial injury and better LVEF with nicorandil suggest improved cardiac resilience to ischemic insults.

PubMed ID: 16169327

Six months of nicorandil improved sympathetic innervation scores and LVEF in ischemic cardiomyopathy — improved myocardial reserve.

PubMed ID: 12851621

IS5MN added to ACE inhibitors reduced post‑MI ventricular dilation and improved EF → increased cardiac resilience.

PubMed ID: 8509566

Oral ISMN acutely lowered BP after suspected MI (short‑lived effect).

PubMed ID: 7866603

ISDN significantly lowered systolic BP (≈9–10% monotherapy, greater with combination).

PubMed ID: 10898408

Shows dramatic BP potentiation when sildenafil is combined with nitrates (safety signal) — demonstrates nitrates' capacity to lower BP substantially.

PubMed ID: 20845295

Sublingual ISDN acutely reduced mean arterial pressure (~−12 mmHg) in men with BPH — clear BP-lowering effect.

PubMed ID: 21240870

Sustained-release ISMN in a randomized dialysis trial meaningfully lowered brachial blood pressure and reduced LV mass and HF events.

PubMed ID: 23296279

Oral nitrates in hypertensive CAPD patients reduced BP and decreased antihypertensive drug burden—strong clinical BP effect.

PubMed ID: 28100019

HVPG‑guided therapy using nitrates as part of regimen achieved greater HVPG reductions and improved outcomes—indirect blood‑pressure/portal‑pressure benefit.

PubMed ID: 15215814

ACE inhibitors altered NO-pathway markers and oxidative stress with BP-lowering context (indirect relevance to nitrate effects).

PubMed ID: 32729923

Randomized 60-day trial showed large (~10 mmHg) ambulatory systolic BP reductions — strong, high-quality evidence.

PubMed ID: 32386891

One-week increased dietary nitrate reduced postprandial BP in healthy adults.

PubMed ID: 8483018

Review notes long‑acting nitrates selectively reduce systolic BP and increase arterial compliance (qualitative evidence).

PubMed ID: 11589843

Apomorphine produced additional standing BP drops in men on long‑acting nitrates — supports clinically meaningful BP‑lowering effect of nitrates (additive hazard).

PubMed ID: 18250365

Beetroot juice produced marked acute systolic/diastolic/MAP reductions with corresponding plasma NOx rise.

PubMed ID: 7921519

Oral nicorandil produced dose‑dependent BP reductions in healthy volunteers.

PubMed ID: 22019438

Acute spinach ingestion reduced systolic BP alongside improved endothelial markers.

PubMed ID: 8806342

Randomized trial showed sublingual nitrate forms significantly lowered aortic systolic BP; practical effect modifier (wet mouth) quantified.

PubMed ID: 14642699

Tadalafil potentiated nitroglycerin-induced BP drops; demonstrates nitrates' potent BP-lowering effects (clinically important interaction).

PubMed ID: 20585108

Randomized crossover study showed dose-dependent BP reductions with inorganic nitrate (KNO3/beetroot) — strong direct evidence.

PubMed ID: 2178930

ISMN acutely lowered systolic/diastolic BP after MI in a large trial—direct BP-lowering effect though no mortality benefit.

PubMed ID: 35258101

Sublingual nitroglycerin produced transient SBP reductions ≈6–10 mmHg—strong pharmacologic BP effect.

PubMed ID: 35869311

Daily concentrated beetroot juice produced a small reduction in diastolic BP (≈−3.7 mmHg) though modest and not robust after adjustment.

PubMed ID: 33620131

Nitroglycerin produced expected acute BP reductions during infusion—consistent nitrate pharmacology.

PubMed ID: 32524226

Intermittent hypoxia raised NOx and produced notable systolic BP reductions—evidence that NOx elevation can lower BP.

PubMed ID: 32694343

Aerobic training raised NOx and produced clinically meaningful ambulatory SBP reductions; supports NOx-mediated BP lowering.

PubMed ID: 29858919

IV nicorandil caused significant systolic BP reductions during hyperemia — potent vasodilatory effect.

PubMed ID: 30554386

Jump-rope program increased NOx and reduced systolic BP in prehypertensive adolescents — exercise + NO link to BP reduction.

PubMed ID: 28590143

Exercise program (increased NOx) lowered SBP in obese prehypertensive adolescents—supports NO-pathway involvement in BP reduction (indirect).

PubMed ID: 21371681

Pooled trials showed naproxcinod maintained systolic BP similar to placebo and lower than naproxen in some subgroups—supportive of BP benefit from NO‑donor pharmacology.

PubMed ID: 21545399

NO‑donating NSAID (naproxcinod) produced modestly lower systolic BP vs naproxen (small but measurable effect).

PubMed ID: 20832994

IV nicorandil decreased systolic BP in acute heart failure patients in the small randomized trial.

PubMed ID: 20202489

Naproxcinod showed BP profile similar to placebo (did not raise BP like naproxen), indicating beneficial BP effects for an NO‑donor NSAID.

PubMed ID: 19733721

Naproxcinod avoided the SBP increases seen with naproxen and reduced incidence of ≥10 mmHg SBP rises versus naproxen.

PubMed ID: 19410035

Transdermal glyceryl nitrate produced more hypotension and headaches vs placebo (demonstrates blood‑pressure lowering effect of organic nitrate in RCT context).

PubMed ID: 11511432

Hemodynamic comparison found nitrates decreased systemic vascular resistance and produced larger MAP drops compared with tezosentan/nesiritide groups — supports BP‑lowering effect but with hemodynamic tradeoffs.

PubMed ID: 8077066

Oral nicorandil produced clear dose‑related, quantified falls in arterial systolic pressure (up to ~31 mmHg).

PubMed ID: 1899644

Transdermal nitroglycerin systems reduced exercise pulmonary artery pressure acutely (and altered ischaemia metrics); reflects vasodilatory pressure effects.

PubMed ID: 1909152

Intermittent transdermal NTG lowered resting systolic BP by ~7.5 mmHg — pharmacologic nitrate lowering BP when used intermittently.

PubMed ID: 2127377

Sublingual nitroglycerin rapidly reduced LV pressures; correlates with BP lowering effect.

PubMed ID: 38123239

12-week BRJ lowered home systolic BP by ~4.5 mmHg and improved vascular indices in COPD—robust chronic BP effect.

PubMed ID: 36958967

13‑week trial showed clinic systolic BP reductions with low/medium nitrate doses—evidence of sustained BP lowering in older overweight adults.

PubMed ID: 37120928

Acute beetroot dose lowered brachial systolic BP in young men (effect driven by males) — acute antihypertensive effect in subgroup.

PubMed ID: 36629601

Acute central systolic BP reduced and subendocardial perfusion improved in hypertensives—clear hemodynamic BP benefit.

PubMed ID: 34236392

Twelve-week high-nitrate vegetable intervention modestly lowered daytime and 24-h systolic BP (clinically relevant).

PubMed ID: 32376732

COPD trial showed a clear systolic BP reduction (~−7 mmHg) alongside functional benefits—strong clinical BP evidence in that context.

PubMed ID: 32758038

One week nitrate reduced blood-pressure variability and lowered BP fluctuations in TIA patients.

PubMed ID: 33183558

12-week plant-based inorganic nitrate produced clinically meaningful reductions in SBP and DBP in hypertensive participants.

PubMed ID: 31408838

Three days of sodium nitrate ingestion produced a statistically significant systolic BP decrease (p=0.015) despite no BOLD changes.

PubMed ID: 28683960

Inorganic nitrite acutely lowered wave reflection and systemic vascular resistance and improved hemodynamics; BP/afterload-related benefits reported.

PubMed ID: 26607938

6‑week beetroot improved FMD and reduced SBP by ~4.1 mmHg in people with high cholesterol (meaningful vascular/BP effect).

PubMed ID: 25421976

4‑week RCT in hypertensives: sustained ~7–8 mmHg reductions in systolic BP with raised plasma nitrite and cGMP (strong evidence).

PubMed ID: 28617765

Oral nicorandil before PCI improved microvascular reperfusion and reduced oxidative markers, indicating better tissue perfusion.

PubMed ID: 8627976

Intracoronary nicorandil produced dose-dependent coronary dilation comparable to ISDN — supports improved coronary perfusion.

PubMed ID: 7788038

SPECT showed a substantial (~24%) reduction in exercise-induced perfusion defect size — direct evidence of improved regional perfusion/nutrient delivery.

PubMed ID: 9875113

Sublingual ISDN spray produced reliable coronary dilation, indicating improved conduit blood supply to myocardium (relevant to nutrient delivery).

PubMed ID: 23296279

Oral nitrates in dialysis patients reduced LV mass and BP and lowered ADMA, consistent with improved vascular function and tissue perfusion.

PubMed ID: 23806384

Dietary/inorganic nitrate raised plasma nitrite and produced NO-mediated vascular/platelet effects consistent with improved microvascular flow.

PubMed ID: 40123490

Isosorbide mononitrate reduced radial graft failure implying vascular-protective effects that could support tissue perfusion.

PubMed ID: 9809945

Increased NO biomarkers with markedly improved walking distances in claudication consistent with improved limb perfusion/nutrient delivery.

PubMed ID: 10402369

Oral L-arginine raised follicular NOx and improved Doppler flow and oocyte/embryo yield → improved microvascular delivery to follicles.

PubMed ID: 12419572

Acute oral L-arginine improved endothelium-dependent dilation — likely improves microvascular nutrient delivery.

PubMed ID: 10080465

Peri-PCI nicorandil improved myocardial recovery and reduced no-reflow, consistent with improved tissue perfusion.

PubMed ID: 24457276

Nicorandil reduced index of microcirculatory resistance after PCI, indicating improved microvascular perfusion.

PubMed ID: 29976553

Improved ankle–brachial index and walking distance in PAD suggests enhanced limb perfusion and nutrient delivery.

PubMed ID: 32729923

Sustained nitrate raised plasma nitrate and markedly lowered ambulatory BP — implies improved tissue perfusion and delivery.

PubMed ID: 32386891

One-week dietary nitrate increased plasma nitrite/nitrate and reduced postprandial BP — supports improved postprandial perfusion.

PubMed ID: 1282609

Pre‑treatment with nitrates reduced post‑ischaemic stunning after angioplasty, implying protection via maintained perfusion/nutrient delivery.

PubMed ID: 8181883

Intermittent nitroglycerin increased time to ischemia and exercise duration consistent with improved myocardial perfusion/nutrient delivery.

PubMed ID: 32326664

Ubiquinol raised NOx and FMD, consistent with improved microvascular delivery.

PubMed ID: 18250365

Beetroot (dietary nitrate) raised plasma nitrite/nitrate and lowered BP, implying improved microvascular perfusion.

PubMed ID: 15589858

Estrogen substantially increased NO metabolites and improved vasodilation in younger subjects, consistent with better microvascular delivery.

PubMed ID: 20585108

Inorganic nitrate raised plasma nitrite and cGMP consistent with vasodilatory mechanisms that plausibly improve microvascular perfusion and thus nutrient delivery.

PubMed ID: 22019438

Nitrate-rich spinach acutely increased plasma nitrite/RXNO and improved endothelial function (FMD), supporting improved microvascular nutrient delivery.

PubMed ID: 24286591

Hypoxic exercise increased NO metabolites and improved cardiac/muscle blood flow distribution, supporting improved nutrient delivery to muscle.

PubMed ID: 32866396

Single dose beetroot improved endothelial-dependent FMD, supporting enhanced microvascular delivery capacity.

PubMed ID: 33183558

12-week nitrate complex improved endothelial function in hypertensives, consistent with better nutrient/flow delivery.

PubMed ID: 36629601

Improved microvascular perfusion and subendocardial viability in hypertensives suggests enhanced tissue perfusion/nutrient delivery.

PubMed ID: 36958967

13‑week trial showed improved microvascular endothelial perfusion with low/medium nitrate doses (direct evidence of improved local nutrient flow).

PubMed ID: 38123239

COPD trial showed improved endothelial markers (RHI/AIx) and walking distance, implying better tissue perfusion.

PubMed ID: 28959158

Pre-workout supplement acutely raised plasma NOx and increased femoral artery blood flow after heavy resistance exercise — consistent with improved nutrient delivery.

PubMed ID: 8006274

Intermittent NTG reduced myocardial perfusion defects on imaging, implying better regional nutrient/perfusion delivery.

PubMed ID: 9064947

IV nitroglycerin produced immediate and sustained epicardial dilation indicating increased coronary blood delivery potential.

PubMed ID: 9107166

Sublingual nitroglycerin improved detection and reversal of myocardial perfusion defects — implies better regional perfusion.

PubMed ID: 11557681

Raloxifene/HRT raised plasma nitrite/nitrate and improved flow‑mediated dilation (FMD), supporting improved microvascular delivery via enhanced endothelial NO signaling (indirect to nitrate supplementation).

PubMed ID: 12052481

Genistein increased plasma nitrite/nitrate and improved flow-mediated vasodilation, supporting improved microvascular delivery (biomarker + FMD).

PubMed ID: 15661417

Tadalafil increased flow‑mediated dilation and plasma nitrite/nitrate, indicating improved endothelium-dependent perfusion.

PubMed ID: 17967610

Intracoronary nicorandil reduced no‑reflow and microvascular issues, consistent with improved microvascular perfusion (nutrient delivery).

PubMed ID: 17478142

IV nicorandil before PCI prevented microvascular impairment, supporting improved tissue perfusion.

PubMed ID: 20728082

Improved nitrate‑mediated dilatation (endothelium‑independent) implies enhanced conduit vasodilation and potential nutrient delivery.

PubMed ID: 30987432

Nicorandil reduced contrast-induced kidney injury after PCI, implying improved organ perfusion/nutrient delivery to kidneys.

PubMed ID: 33847683

Intracoronary nicorandil improved myocardial perfusion metrics, indicating improved local nutrient/flow delivery.

PubMed ID: 15676171

NO‑donor improved exercise parameters in trials — translates to better athletic/exercise performance potential.

PubMed ID: 8087821

Large increases in exercise duration and reduced ischemic symptoms suggest more efficient work capacity for a given effort in cardiac patients.

PubMed ID: 1927943

Longer exercise times with nitroglycerin indicate potential to enhance performance in clinical exercise contexts (angina patients); applicability to healthy athletic performance is indirect.

PubMed ID: 1909152

Intermittent NTG regimen avoided tolerance and improved exercise duration vs continuous dosing — efficiency preserved by avoiding tolerance.

PubMed ID: 35512758

Triathletes had better running economy and longer cycling TTE after 7-day beetroot—meaningful performance gains in trained athletes.

PubMed ID: 29412076

Beetroot reduced time-to-peak power in sprint tests (~2.8% faster), an ergogenic change relevant to athletic performance onset.

PubMed ID: 27777094

Modest but statistically significant improvements in multiple sprint distances and Yo‑Yo test in team‑sport players indicate performance benefit.

PubMed ID: 27034623

Creatine‑nitrate group had measurable gains in bench‑press power and lifting volume over 28 days—performance benefit, though creatine confounds attribution to nitrate.

PubMed ID: 40733006

Four‑week nitrate+citrulline in professional players improved max speed and preserved anaerobic power post‑match — directly relevant to performance.

PubMed ID: 35010917

9‑week combined citrulline + nitrate extract improved VO2max and some strength/endurance measures in trained athletes.

PubMed ID: 8370370

Nicorandil (nitrate donor) improved exercise capacity and reduced angina attacks over 3 months — pro‑performance effect in cardiac patients.

PubMed ID: 29976553

Functional walking improvements in PAD when beetroot was added to exercise indicate meaningful real-world performance gains.

PubMed ID: 28327503

Trained soccer players covered more distance in Yo-Yo IR1 after beetroot; clear sport-relevant performance gain.

PubMed ID: 11208406

Longer walking times to ischemia with ISDN imply more efficient exercise (more work before ischemia).

PubMed ID: 9830234

Improved exercise duration in patients could translate to performance gains, but population (angina) differs from athletes.

PubMed ID: 8256699

Extended‑release ISMN delivered measurable exercise gains with stable dosing—improving practical efficiency.

PubMed ID: 35010917

9‑week citrulline + nitrate‑rich beetroot improved estimated VO2max and some performance metrics — supports reduced perceived fatigue.

PubMed ID: 40733006

4 weeks nitrate+citrulline preserved anaerobic power after matches, suggesting less post‑match fatigue.

PubMed ID: 36364742

Eight weeks in T2DM produced a modest ~5% VO2max increase that can translate to less perceived fatigue during activity.

PubMed ID: 1909152

Intermittent (nocturnal free) NTG improved exercise metrics versus continuous dosing — likely reduces exertional fatigue vs tolerant regimens.

PubMed ID: 8087821

Marked reduction in angina and increased exercise duration could translate to improved daily energy in symptomatic patients.

PubMed ID: 15676171

Molsidomine (NO‑donor) trials showed improved exercise tolerance and fewer angina attacks — plausible reduction in exertional fatigue.

PubMed ID: 9830234

Controlled‑release ISMN improved exercise duration in angina patients — likely to reduce exertional fatigue (moderate indirect evidence).

PubMed ID: 32731478

Beetroot-containing drinks increased frontal oxygenation and reduced mental fatigue (beetroot = dietary nitrate, but mixed actives).

PubMed ID: 9809945

Improved walking distance in claudication implies reduced exertional fatigue in affected patients.

PubMed ID: 29976553

PAD patients showed larger increases in walking distance when beetroot was added to exercise, suggesting reduced exertional fatigue.

PubMed ID: 1350882

Intermittent transdermal nitrate reduced ambulatory ischemic episodes and preserved symptomatic benefit (less fatigue from ischemia).

PubMed ID: 8181883

Intermittent transdermal nitrates increased exercise duration/time to angina (less exertional fatigue in angina patients).

PubMed ID: 10080465

Improved myocardial recovery and fewer adverse outcomes after MI when nicorandil used — faster organ recovery evidence.

PubMed ID: 16936418

Nicorandil improved reperfusion markers and ST resolution after reperfusion, consistent with faster recovery after ischemic insult.

PubMed ID: 28959158

Supplement increased post-exercise femoral blood flow after heavy resistance, which could facilitate recovery processes (indirect, confounded).

PubMed ID: 40209616

Accelerated blister resolution and preserved endothelial function during inflammation indicate faster tissue recovery processes.

PubMed ID: 40733006

Nitrate+citrulline preserved anaerobic power the day after matches and increased maximal speed — strong evidence for faster recovery from sprint efforts.

PubMed ID: 28719765

Beetroot juice reduced subjective muscle soreness after eccentric exercise, consistent with faster functional recovery.

PubMed ID: 10958273

Nicorandil improved metabolic recovery and LV function after PTCA — analogous to faster tissue recovery post-ischemia/exercise.

PubMed ID: 21272053

Pharmacometric modeling links naproxcinod concentrations to analgesic effects; supports the NO‑donor analgesic mechanism (indirect).

PubMed ID: 28719765

Beetroot juice attenuated pressure-pain thresholds after eccentric exercise more than nitrate-only or placebo, indicating less soreness.

PubMed ID: 20202489

Naproxcinod produced clear symptomatic benefit for osteoarthritis pain; however, effect is confounded by NSAID component.

PubMed ID: 20828790

Naproxcinod (an NO‑donating NSAID) reduced osteoarthritis pain and improved function—supports analgesic effect relevant to soreness.

PubMed ID: 22484579

Perioperative nicorandil reduced biochemical brain-injury markers and preserved short-term cognitive scores compared with control (small trial).

PubMed ID: 37875637

Acute chewable beetroot improved immediate and delayed verbal memory and frontal-executive tasks in healthy adults.

PubMed ID: 26037632

Single beetroot drink acutely modulated frontal cortex haemodynamics and improved one arithmetic task measure.

PubMed ID: 32758038

One week nitrate reduced BP/brain-flow fluctuations and improved cerebral autoregulation in TIA patients, which can support cognitive stability.

PubMed ID: 36839248

Improved executive cognitive performance (TMT-B) in overweight older adults receiving beetroot during caloric restriction—direct cognitive signal.

PubMed ID: 32731478

Beetroot + phenolic beverages increased frontal oxygenation and improved some mood/fatigue measures, supporting attention/alertness.

PubMed ID: 27034623

Creatine‑nitrate (higher dose) produced modest increases in bench‑press power and lifting volume over 28 days; nitrate likely contributed to raised plasma nitrate but creatine is a major confounder.

PubMed ID: 9583444

Nicorandil given at reperfusion produced small but significant improvements in regional myocardial contraction.

PubMed ID: 35010917

Chronic supplementation improved maximal jump and some strength/endurance tests in trained athletes.

PubMed ID: 40733006

Preserved Wingate anaerobic power and increases in Vmax indicate maintenance/enhancement of explosive outputs.